Adverse event reporting for botulinum toxin type A

Journal of the American Academy of Dermatology

Volumn 53, Issue 6, 2005, Pages 1080-1082

  Batra, R Sonia ^a,b   Dover, Jeffrey S ^c,d,e   Arndt, Kenneth A ^c,d,e,f  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SKINCARE PHYSICIANS   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CYCLOOXYGENASE 2 INHIBITOR; FENFLURAMINE; PHENTERMINE; ROFECOXIB; TEMAFLOXACIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLEPHAROSPASM; CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEATH; DERMATOLOGY; DRUG EFFICACY; DRUG EXPOSURE; DRUG LABELING; DRUG SAFETY; DYSTONIA; FACIAL NERVE PARALYSIS; FOOD AND DRUG ADMINISTRATION; HEMOLYTIC ANEMIA; HUMAN; INFORMATION PROCESSING; LOW DRUG DOSE; META ANALYSIS; MUSCLE WEAKNESS; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STRABISMUS; SYSTEMATIC REVIEW; VALVULAR HEART DISEASE;

EID: 27944453963     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.08.036     Document Type: Editorial

References (22)

1. American Society for Aesthetic Plastic Surgery. 2003 ASAPS Statistics - Cosmetic Procedures. Available at: http://www.ebreastaug.com/breast- augmentation/asapsstatistics.html. Accessed August 8, 2005.
2. T.R. Coté, A.K. Mohan, J.A. Polder, M.K. Walton, and M.M. Braun Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases J Am Acad Dermatol 53 2005 407 415
3. R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, and K. Horgan Cardiovascular events associated with rofecoxib in colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102
4. D.J. Graham, and L. Green Further cases of valvular heart disease associated with fenfluramine-phentermine N Engl J Med 337 1997 635
5. M.D. Blum, D.J. Graham, and C.A. McCloskey Temafloxacin syndrome: review of 95 cases Clin Infect Dis 18 1994 946 950
6. D.A. Kessler Introducing MEDWATCH: a new approach to reporting medication and device adverse effects and product problems JAMA 269 1993 2765 2768
7. T. Brewer, and G.A. Colditz Postmarketing surveillance and adverse drug reactions JAMA 281 1999 824 829
8. R. Temple Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance JAMA 281 1999 841 844
9. B. Case, and M.A. Oszko Use of algorithm to evaluate published reports of adverse drug reactions Am J Hosp Pharm 48 1991 121 122
10. J.A. Berlin, and G.A. Colditz The role of meta-analysis in the regulatory process for foods, drugs, and devices JAMA 281 1999 830 834
11. M. Naumann, and J. Jankovic Safety of botulinum toxin type A: a systematic review and meta-analysis Curr Med Res Opin 20 2004 981 990
12. Tansey B. Hard Sell. How marketing drives the pharmaceutical industry. San Francisco Chronicle, May 1, 2005. Available at: http://www.sfgate.com. Accessed August 8, 2005.
13. National Center for Policy Analysis. Brief analysis No. 214. Available at: http://www.hcpa.org/ba/ba214.html. Accessed August 9, 2005.
14. A. Carruthers, and J.A. Carruthers Treatment of glabellar frown lines with C. Botulinum A exotoxin J Dermatol Surg Oncol 21 1992 276 278
15. A. Carruthers, and J. Carruthers Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin Dermatol Surg 24 1998 1189 1194
16. A.W. Klein Dilution and storage of botulinum toxin Dermatol Surg 21 1998 1179 1180
17. M. Alam, J.S. Dover, and K.A. Arndt Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative Arch Dermatol 13 2002 510 514
18. J.A. Carruthers, N.J. Lowe, M.A. Menter, J. Gibson, M. Nordquist, and J. Mordaunt A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines J Am Acad Dermatol 46 2002 840 849
19. D.M. Hexsel, A.T. De Almeida, M. Rutowitsch, I.A. De Castro, V.L. Silveira, and D.O. Gobatto Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application Dermatol Surg 29 2003 523 529
20. A. Carruthers, J. Carruthers, and S. Said Dose ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females Dermatol Surg 31 2005 414 422
21. M. Naumann, N.J. Lowe, C.R. Kumar, and H. Hamm Hyperhidrosis Clinical Investigators Group. Botulinum toxin type a is a safe and effective treatment for axillary hyperhydrosis over 16 months: a prospective study Arch Dermatol 139 2003 731 736
22. G.R. Venning Identification of adverse reactions to new drugs. IV - Verification of suspected adverse reactions BMJ 286 1983 544 547